Merck announces first presentation of results from Phase 3 CORALreef HeFH

Merck (MRK), known as MSD outside of the United States and Canada, announced the first presentation of results from the Phase 3 CORALreef HeFH trial demonstrating that treatment with enlicitide decanoate, an investigational, once-daily oral proprotein convertase subtilisin/kexin type 9, PCSK9, inhibitor, resulted in a statistically significant and clinically meaningful reduction in low-density lipoprotein cholesterol, LDL-C, of 59.4% compared to placebo at week 24 in adults with heterozygous familial hypercholesterolemia, HeFH. The effect size and safety profile was comparable to that observed in the pivotal Phase 3 CORALreef Lipids study. These late-breaking data will be presented for the first time today at the American Heart Association, AHA, Scientific Sessions 2025 and published simultaneously in the Journal of the American Medical Association.